Michael Sayler, DO
Family Medicine · Broken Arrow, OKNPI 1770840944
Payments from drug & device makers
Across 620 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- Novo Nordisk$993
- Pfizer$947
- Lilly USA, LLC$844
- Amgen$484
- plus $4K from 32 others
What the payments were for
- Food & beverage$9,271100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,166 |
| GSK | 84 | $1,014 |
| Novo Nordisk | 72 | $993 |
| Pfizer | 62 | $947 |
| Lilly USA, LLC | 57 | $844 |
| Amgen | 34 | $484 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $470 |
| AstraZeneca | 20 | $394 |
| Merck | 28 | $354 |
| Johnson & Johnson | 21 | $325 |
| Abbott | 16 | $248 |
| Boehringer Ingelheim | 17 | $238 |
| Bayer | 14 | $229 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $187 |
| Astellas Pharma US Inc | 10 | $168 |
| Exact Sciences | 9 | $138 |
| Genentech USA, Inc. | 9 | $134 |
| Alk-abello, Inc | 5 | $118 |
| Otsuka America Pharmaceutical, Inc. | 5 | $105 |
| Arbor Pharmaceuticals, Inc. | 2 | $88 |
| Dynavax Technologies Corporation | 5 | $80 |
| Eisai Inc. | 5 | $65 |
| Corium, LLC | 2 | $62 |
| Lundbeck LLC | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $44 |
| Dexcom, Inc. | 2 | $37 |
| Avanir Pharmaceuticals, Inc. | 2 | $36 |
| Shire North American Group Inc | 2 | $32 |
| Sanofi Pasteur Inc. | 2 | $31 |
| Novartis | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 2 | $22 |
| Sanofi | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$9,280 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $151,416 |
| OzempicSemaglutide | 88 | $104,204 |
| XareltoRivaroxaban | 108 | $100,181 |
| TrulicityDulaglutide | 52 | $67,429 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $65,028 |
| FarxigaDapagliflozin Propanediol | 58 | $50,782 |
| MounjaroTirzepatide | 38 | $41,662 |
| RybelsusSemaglutide | 32 | $38,868 |
| JardianceEmpagliflozin | 18 | $27,667 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $18,934 |
| Atorvastatin Calcium | 529 | $14,679 |
| Rosuvastatin Calcium | 344 | $13,117 |
| JanuviaSitagliptin Phosphate | 11 | $12,032 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,796 |
| Amlodipine Besylate | 518 | $5,392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $947 | $151,416158 claims |
| Novo NordiskOzempic, Rybelsus | $993 | $143,071120 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $844 | $109,09190 claims |
| Johnson & JohnsonXarelto | $325 | $100,181108 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,014 | $69,97770 claims |
| AstraZenecaFarxiga | $394 | $50,78258 claims |
| Boehringer IngelheimJardiance | $238 | $27,66718 claims |
| MerckJanuvia | $354 | $12,03211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $470 | $6,79614 claims |
| AbbVieSynthroid | $1,166 | $2,07927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Broken Arrow
- James CampbellBroken Arrow$35K
- Corey ChamnessBroken Arrow$20K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.